Sustained therapeutic response to osimertinib treatment in metastatic pulmonary adenocarcinoma – case presentation
Metastatic non-small cell lung cancer (NSCLC) remains an incurable disease; however, the introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)